Phase 1
N=600
MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
Solid Tumors
Bottom Line
View on ClinicalTrials.gov: NCT02517398 ↗Enrolled (actual)
600
Serious AEs
59.5%
Results posted
May 2024
Primary outcome: Primary: Dose-escalation: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs — 3; 3; 4; 3 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 1
- Interventions
- MSB0011359C (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- EMD Serono Research & Development Institute, Inc.
- Primary completion
- May 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Dose-escalation: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs |
3; 3; 4; 3; 6; 10 | — |
| PRIMARY Dose-escalation: Number of Participants With Treatment-Related TEAEs, Treatment-Related Serious TEAEs and Treatment-related TEAEs Leading to Death |
2; 0; 2; 2; 5; 6 | — |
| PRIMARY Number of Participants With TEAEs and Related TEAEs Based on Severity According to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version 4.03 |
3; 3; 2; 1; 4; 7 | — |
| PRIMARY Dose-escalation: Number of Participants With Dose-Limiting Toxicities According to the National Cancer Institute Common Terminology Criteria For Adverse Events(NCI-CTCAE), v4.03 |
0; 0; 0; 1; 0; 0 | — |
| PRIMARY Dose-expansion: Number of Participants With Best Overall Response (BOR) as Assessed by Independent Endpoint Review Committee (IRC) |
0; 0; 0; 0; 0; 0 | — |
| PRIMARY Dose-expansion: Disease Control Rate According to Response Assessment in Neuro-Oncology (RANO) as Adjudicated by the IRC for Participants With Glioblastoma |
22.9 | — |
| SECONDARY Maximum Concentration (Cmax) of M7824 in Plasma |
7.08; 22.5; 92.8; 233; 503; 766 | — |
| SECONDARY Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) of M7824 |
747; 3170; 11000; 32600; 62200; 114000 | — |
| SECONDARY Apparent Terminal Half Life (t1/2) of M7824 |
74.0; 120; 125; 160; 172; 171 | — |
| SECONDARY Trough Plasma Concentration (Ctrough) of M7824 |
NA; 2.92; 10.8; 44.0; 92.8; 164 | — |
| SECONDARY Apparent Plasma Clearance (CL) of M7824 |
0.388; 0.270; 0.222; 0.235; 0.242; 0.194 | — |
| SECONDARY Number of Participants With Positive Anti-Drug Antibody (ADA) of M7824 |
1; 2; 0; 1; 1; 1 | — |
| SECONDARY Number of Participants With Best Overall Response (BOR) as Assessed by Investigator |
0; 0; 0; 0; 1; 0 | — |
| SECONDARY Dose Expansion: Number of Participants With TEAEs and Serious TEAEs |
38; 66; 31; 82; 36; 30 | — |
| SECONDARY Dose Expansion: Number of Participants With Treatment-Related TEAEs, Treatment-Related Serious TEAEs and Treatment-related TEAE Leading to Death |
30; 44; 24; 61; 15; 20 | — |
| SECONDARY Dose Expansion: Number of Participants With TEAEs and Related TEAEs Based on Severity According to NCI-CTCAE Version 4.03 |
29; 52; 15; 62; 31; 26 | — |
Summary
The main purpose of this Phase I study was to test MSB0011359C (M7824) at different dose levels to see if it is safe and well tolerated when given once every 2 weeks. Phase I means the study drug has not previously been given to humans or has only been given to a limited number of people, although it has been extensively studied in animals. Based on this information, it is hoped to find out which dose could be best for the treatment of patients. There are two parts of this research study: a dose-escalation part and an expansion part. Dose escalation means that the first people taking part in the study will receive low doses of the study drug, and as more people take part, the additional participants will receive a higher dose. This is done to find the safest dose for the study drug. Expansion means that after the dose-escalation part of the study has looked at the safety and effectiveness of different doses, many more people will be invited to take part in the study and will receive the study drug at the safest dose. Additional purposes of the study are to find out whether the study drug has anti-cancer effects and how the study drug is processed by the body.
Eligibility Criteria
Inclusion Criteria
- Ability to understand the purpose of the study, provide signed and dated informed consent, and able to comply with all procedures
- In Japan, if a subject is =) 18 years
- Life expectancy >= 12 weeks as judged by the Investigator
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at trial entry
- Disease must be measurable with at least 1 uni dimensional measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Adequate hematological, hepatic and renal function as defined in the protocol
- Effective contraception for both male and female subjects if the risk of conception exists
Other protocol-defined inclusion criteria could apply.
Exclusion Criteria
- Concurrent treatment with non-permitted drugs and other interventions
- Anticancer treatment within 28 days before the start of trial treatment, for example cyto reductive therapy, radiotherapy (with the exception of palliative radiotherapy delivered in a normal organ-spearing technique), immune therapy, or cytokine therapy
- Major surgery within 28 days before the start of trial treatment (prior diagnostic biopsy is permitted)
- Systemic therapy with immunosuppressive agents within 7 days before the start of trial treatment; or use of any investigational drug within 28 days before the start of trial treatment
- Previous malignant disease (other than the target malignancy to be investigated in this trial) within the last 3 years. Subjects with history of cervical carcinoma in situ, superficial or non invasive bladder cancer or basal cell or squamous cell cancer in situ previously treated with curative intent are NOT excluded. Subjects with other localized malignancies treated with curative intent need to be discussed with the Medical Monitor.
- Rapidly progressive disease which, in the opinion of the Investigator, may predispose to inability to tolerate treatment or trial procedures
- Subjects with active central nervous system (CNS) metastases causing clinical symptoms or metastases that require therapeutic intervention are excluded
- Receipt of any organ transplantation, including allogeneic stem-cell transplantation, but with the exception of transplants that do not require immunosuppression (eg, corneal transplant, hair transplant)
Other protocol-defined exclusion criteria could apply
Data sourced from ClinicalTrials.gov (NCT02517398). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.